BRISTOL-MYERS SQUIBB CO

Julia Haller’s insider share purchase shows confidence in Bristol‑Myers Squibb, while the PD‑L1 assay market is set to double, offering investors and clinicians new growth and precision‑oncology opportunities.

Discover how Bristol‑Myers Squibb’s 2025 employee benefit updates boost net assets, cut admin fees, and align with value‑based healthcare trends—boosting talent, retention, and investor confidence.

Explore Bristol‑Myers Squibb’s breakthrough: mezigdomide’s success in relapsed myeloma and a bold Opdivo partnership targeting melanoma resistance.

FDA approves weekly self‑injection of Saphnelo (anifrolumab) for SLE, offering the same proven safety and efficacy of the IV drug with greater convenience for patients.

Corporate‑Market Update: Bristol‑Myers Squibb (BMY) shows steady institutional inflows, routine insider transactions, bullish call‑option volume, and solid revenue growth despite a modest EPS miss, underscoring continued confidence in BMY’s pipeline…

Volatile BMY trading, mixed analyst sentiment, and pipeline insights—discover how Bristol‑Myers Squibb balances speculation, earnings, and pharma innovation.

Explore how Bristol‑Myers Squibb’s Camzyos Phase 3 success could reshape its portfolio, opening a high‑margin pediatric cardiology niche and reducing oncology dependence.

Explore Bristol‑Myers Squibb’s 12(g) deregistration, new mental‑health partnership, and Pictet’s investment, revealing how the pharma giant is cutting compliance costs while boosting value‑based care.

Discover how Bristol‑Myers Squibb’s partnership with NCMWB could reshape schizophrenia treatment with peer‑support, predictive analytics, and new revenue streams by 2027.

Discover why Bristol‑Myers Squibb’s $0.63 dividend, Barclays praise, and steady ownership shifts signal strong investor confidence and stable stock performance.